The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.
FDA reveals it warned Corcept Therapeutics multiple times about relacorilant's approval issues before the company submitted its Cushing's syndrome drug application.
Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.
FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.
